SCHEDULE 13D: Activist Investor BML Capital Management Urges ESSA Pharma to Liquidate and Return Capital

BML Investment Partners, L.P., holding a 9.5% stake in ESSA Pharma Inc., has filed a Schedule 13D advocating for the company's liquidation or sale to return capital to shareholders.

Summary

• BML Investment Partners, L.P. (BML) has acquired 4,221,546 common shares of ESSA Pharma Inc., representing 9.5% of the outstanding shares.
• The shares were acquired using $6,476,584 of working capital.
• BML's primary purpose for this investment is for investment purposes in the ordinary course of business.
• On April 24, 2025, BML sent a letter to ESSA Pharma's Board of Directors, expressing its belief that an orderly winddown, liquidation, and capital return is in the best interests of shareholders.
• BML would also support a sale of the company or a large special dividend as alternatives to quickly return the majority of the company's cash to shareholders.
• The reporting persons reserve the right to acquire or dispose of additional securities or formulate other plans regarding the Issuer.

Sentiment

Score: 3

Explanation: The sentiment is negative towards the company's current strategic direction, as a significant shareholder is advocating for liquidation or sale, indicating a lack of confidence in its ongoing operations and a desire for immediate capital return.

Positives

• For shareholders aligned with BML's view, the proposal for liquidation, sale, or special dividend could lead to a quicker return of capital.
• The investor's active engagement could potentially unlock shareholder value if the proposed actions are pursued.

Negatives

• The call for liquidation or sale suggests a lack of confidence from a significant shareholder in the company's current strategic direction or ability to create value through ongoing operations.
• Such a proposal could create uncertainty for the company's employees, ongoing projects, and future prospects if not handled strategically.

Risks

• Strategic Uncertainty: The public call for liquidation or sale introduces significant strategic uncertainty for ESSA Pharma Inc., potentially impacting its operations, partnerships, and employee morale.
• Shareholder Disagreement: There is a risk of disagreement among shareholders regarding the best path forward (liquidation vs. continued operations), which could lead to proxy fights or prolonged instability.
• Market Perception: The activist investor's stance could negatively impact market perception of ESSA Pharma's long-term viability as an independent entity.
• Difficult Market Conditions: The letter explicitly mentions "difficult market conditions," which could complicate any sale or liquidation process, potentially affecting the value realized for shareholders.

Future Outlook

BML Investment Partners, L.P. believes that an orderly winddown, liquidation, and capital return is in the best interests of ESSA Pharma Inc. shareholders, especially given current difficult market conditions. They also indicate support for alternative transactions such as a company sale or a large special dividend to quickly return the majority of the company's cash to shareholders. The reporting persons reserve the right to acquire or dispose of additional securities and formulate other plans regarding the Issuer.

Management Comments

• "BML agrees with recent public suggestions by other large shareholders that a return of the company's capital to shareholders via liquidation is a sensible course of action in today's difficult market conditions."
• "As such, BML would be supportive of such an action, or, in the absence of this, a similar transaction that would quickly return the majority of the company's cash to shareholders, such as a sale of the company or a large special dividend."

Industry Context

The filing highlights a trend of activist investor engagement, particularly in "difficult market conditions," where investors may push for immediate capital returns or strategic changes like liquidation or sale rather than long-term operational growth, especially if they perceive the company's current strategy as underperforming or inefficient. This reflects a broader market environment where capital allocation and shareholder value creation are under intense scrutiny.

Legal Proceedings

• None of BML Investment Partners, L.P., BML Capital Management, LLC, or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding where they were subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the past five years.

Stakeholder Impact

• Shareholders: Potential for immediate capital return if liquidation or sale occurs, but also potential for loss of long-term growth opportunities if the company ceases operations.
• Employees: Significant uncertainty and potential job losses if the company undergoes liquidation or sale.
• Management: Increased pressure to address shareholder concerns and potentially defend the company's current strategy or explore strategic alternatives.
• Creditors: May be impacted by the terms of any liquidation or sale, depending on the company's financial health.

Next Steps

• ESSA Pharma Inc.'s Board of Directors will need to respond to BML's letter and proposal.
• BML Investment Partners, L.P. may acquire or dispose of additional securities of ESSA Pharma Inc.
• BML Investment Partners, L.P. may formulate other plans or proposals regarding ESSA Pharma Inc. or its securities.

Key Dates

Recommendation

Keywords

ESSA Pharma Inc., BML Investment Partners, Schedule 13D, Activist Investor, Shareholder Activism, Liquidation, Capital Return, Special Dividend, Company Sale, Common Shares, Investment